Canadian Halal Investor.

NASDAQ Shariah screener · October 2026

Is Dexcom, Inc. (DXCM) Halal?

PASS

Dexcom, Inc. · NASDAQ: DXCM · Healthcare

The short answer

Yes -- Dexcom, Inc. (DXCM) passes this Shariah stock screen on all three gates. Per its own FY2025 10-K, Dexcom is a medical device company whose core business is designing and commercializing continuous glucose monitoring (CGM) systems for diabetes and metabolic health -- the Dexcom G7 and G7 15 Day systems, the G6, Dexcom ONE+, and the Stelo over-the-counter glucose biosensor -- with no involvement in conventional banking or lending, insurance, alcohol, gambling, pork, tobacco, or weapons. Its separately disclosed interest and dividend income of $112.7M for FY2025 is about 2.42% of its $4,662.0M in total revenue, under the 5% non-compliant income ceiling. Its debt screen passes: $1,396.4M of senior convertible notes and lease obligations is about 4.21% of its ~$33.19B market cap ($86.23, latest close retrieved October 2, 2026), well below the ~33% ceiling. Both third-party screeners that cover it agree: Zoya describes DXCM as Shariah-compliant and Musaffa classifies it as halal (October 2026) -- honestly reported, not invented. Facts only, not a religious ruling.

Gate 1 — Business activity: PASS

Dexcom, Inc. (NASDAQ: DXCM), based in San Diego, California, describes itself in its FY2025 10-K Item 1 as a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. Its products are the Dexcom G7 and G7 15 Day CGM systems (FDA-cleared integrated CGM), the Dexcom G6, the Dexcom ONE+ system in Europe, and Stelo, an over-the-counter glucose biosensor for prediabetes and Type 2 diabetes. Business screen (factual, from the filing): Dexcom's core business is medical devices -- none of its segments involve conventional banking or lending, insurance, alcohol, gambling, pork, tobacco, or weapons. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Dexcom's FY2025 10-K (fiscal year ended December 31, 2025), interest-bearing debt was $1,396.4M -- senior convertible notes of $1,240.9M carrying amount ($1,250.0M principal of the 0.375% notes due 2028; the 2025 notes matured in November 2025 and were repaid in cash) plus $155.5M of lease obligations (finance lease liabilities of $60.5M and operating lease liabilities of $95.0M present value). The $200M revolving credit facility had zero outstanding borrowings. Against a market cap of about $33.19B ($86.23 latest close retrieved October 2, 2026; 384,864,842 shares outstanding per the 10-K cover), debt divided by market cap is about 4.21%, well below the ~33% ceiling. Cash and cash equivalents of $917.7M are about 2.77% of market cap, or about 6.02% including $1,081.0M of short-term marketable securities. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Dexcom's FY2025 10-K separately discloses interest and dividend income of $112.7M in Note 3 (Other Income, Net) against total revenue of $4,662.0M -- about 2.42% of revenue, under the 5% non-compliant income ceiling. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does Dexcom do?

Dexcom, Inc. (NASDAQ: DXCM), based in San Diego, California, describes itself in its FY2025 10-K (Item 1) as a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. Its products include the Dexcom G7 and G7 15 Day Continuous Glucose Monitoring Systems (FDA-cleared integrated CGM systems), the Dexcom G6, the Dexcom ONE+ CGM system sold in Europe, and Stelo, an over-the-counter glucose biosensor launched in August 2024 for adults with prediabetes and Type 2 diabetes who do not use insulin. It also offers Dexcom Share remote monitoring, the Dexcom Follow app, and cloud-based Dexcom Clarity reporting software, plus insulin-delivery integrations with pump and pen partners.

Why does Dexcom pass this Shariah stock screen?

Dexcom passes this Shariah stock screen on all three gates. Its core business is medical devices -- continuous glucose monitoring systems for diabetes and metabolic health -- which is a permissible business activity with no involvement in conventional banking or lending, insurance, alcohol, gambling, pork, tobacco, or weapons. The two financial gates also pass: interest-bearing debt of $1,396.4M is about 4.21% of its ~$33.19B market cap (ceiling ~33%), and separately disclosed interest and dividend income of $112.7M is about 2.42% of its $4,662.0M revenue (ceiling 5%). This is a factual screen, not a religious ruling -- consult a qualified scholar for personal rulings.

What is Dexcom's interest-bearing debt ratio?

Per Dexcom's FY2025 10-K (fiscal year ended December 31, 2025), interest-bearing debt was $1,396.4M: senior convertible notes of $1,240.9M carrying amount ($1,250.0M principal of the 0.375% notes due 2028; the 2025 notes matured in November 2025 and were repaid in cash), plus lease obligations of $155.5M (finance lease liabilities of $60.5M and operating lease liabilities of $95.0M present value, per the lease maturity note). The $200M revolving credit facility had zero outstanding borrowings at year-end. Against a market cap of about $33.19B ($86.23 latest close retrieved October 2, 2026; 384,864,842 shares outstanding per the 10-K cover), debt divided by market cap is about 4.21% -- well below the ~33% ceiling. Cash and cash equivalents of $917.7M are about 2.77% of market cap, or about 6.02% including $1,081.0M of short-term marketable securities.

What is Dexcom's non-compliant income ratio?

Dexcom's FY2025 10-K discloses interest and dividend income separately in Note 3 (Other Income, Net): $112.7M of interest and dividend income on its cash, cash equivalents, and short-term marketable securities portfolio, against total revenue of $4,662.0M -- about 2.42% of revenue, under the 5% non-compliant income ceiling. The remaining $176.6M of other income, net consists of $78.1M net gains on equity investments, $18.3M of interest expense, and $4.1M other income. Gate 3 passes.

Do Zoya, Musaffa, or ShariaPortfolio cover Dexcom?

Zoya covers DXCM and describes it as Shariah-compliant in its current assessment, noting $112.7M of interest income as 2.42% of combined revenue -- matching this page's figure (zoya.finance/stocks/dxcm; the page's displayed assessment date was blank when accessed in October 2026). Musaffa covers DXCM and classifies it as halal as of October 2026 under its AAOIFI methodology (musaffa.com/stock/DXCM/). A web search for DXCM on the ShariaPortfolio screener (spscreener.mxcorporate.com) returned no coverage as of October 2026. All found coverage is consistent with this page's PASS outcome, honestly reported, not invented.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).